LOCOREGIONAL THERAPY WITH POLYETHYLENE-GLYCOL-MODIFIED INTERLEUKIN-2 OF AN INTRADERMALLY GROWING HEPATOCELLULAR-CARCINOMA IN THE GUINEA-PIG INDUCES T-CELL-MEDIATED ANTITUMOR-ACTIVITY

被引:23
作者
BALEMANS, LTM
MATTIJSSEN, V
STEERENBERG, PA
VANDRIEL, BEM
DEMULDER, PHM
DENOTTER, W
机构
[1] UNIV HOSP NIJMEGEN,DEPT MED,DIV MED ONCOL,NIJMEGEN,NETHERLANDS
[2] UNIV UTRECHT HOSP,DEPT PATHOL,3511 GV UTRECHT,NETHERLANDS
关键词
INTERLEUKIN-2; POLYETHYLENE-GLYCOL; LOCOREGIONAL IMMUNOTHERAPY; GUINEA PIG HEPATOMA;
D O I
10.1007/BF01516936
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Therapy with repeated intratumoral and perilymphatic administration of relatively low doses of polyethylene-glycol(PEG)-modified interleukin-2 (IL-2) in the syngeneic guinea pig line 10 (L10) hepatocarcinoma results in significant local tumor growth inhibition and a delay in development of regional lymph node metastases of more than 3 weeks when compared to controls. Occasionally animals are cured of tumor. The mechanism of this antitumor activity was studied . The antitumor activity of locoregionally administered PEG-IL-2 was abrogated by pretreatment with polyclonal anti-thymocyte serum, indicating that the observed tumor growth inhibition was a T-cell-mediated phenomenon. Besides the locoregional tumor growth inhibition, a systemic effect was recorded as the growth of a second tumor cell inoculum at the contralateral side was inhibited as well. Furthermore, those animals cured after PEG-IL-2 therapy developed specific immunity against the L10 tumor and this immunity could be transferred to naive animals by spleen cells. Immunohistological observations of the tumor site revealed a slight increase of helper and cytotoxic T cell subpopulations after PEG-IL-2 therapy. More pronounced, however, was the rise in number of eosinophilic granulocytes present in the stroma surrounding the tumor cells. Involvement of cytotoxic cells in the antitumor effects of PEG-IL-2 could not be demonstrated: regional lymph node cells and spleen cells obtained immediately after therapy (day 15) or on day 21 showed no cytotoxic activity in vitro against L10, K562, Daudi and line 1 (L1) target cells. In conclusion, locoregional therapy with PEG-IL-2 induced a systemic T-cell-mediated antitumor response. As no cytotoxic T cell activity was measured, however, the underlying mechanism is most likely a T-helper response. Eosinophils at the tumor site may be tumoricidal but further experiments must reveal the role of these cells in the PEG-IL-2-induced tumor regression.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 44 条
  • [31] SPIESS PJ, 1987, JNCI-J NATL CANCER I, V79, P1067
  • [32] TUMOR INFILTRATING LEUKOCYTES (TILS) DURING PROGRESSIVE TUMOR-GROWTH AND BCG-MEDIATED TUMOR-REGRESSION
    STEERENBERG, PA
    DEJONG, WH
    ELGERSMA, A
    BURGER, R
    POELS, LG
    CLAESSEN, AME
    DENOTTER, W
    RUITENBERG, EJ
    [J]. VIRCHOWS ARCHIV B-CELL PATHOLOGY INCLUDING MOLECULAR PATHOLOGY, 1990, 59 (04) : 185 - 194
  • [33] TUMOR REJECTION AFTER ADOPTIVE TRANSFER OF LINE-10-IMMUNE SPLEEN-CELLS IS MEDIATED BY 2 T-CELL SUBPOPULATIONS
    STEERENBERG, PA
    GEERSE, E
    DEJONG, WH
    BURGER, R
    SCHEPER, RJ
    DENOTTER, W
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 34 (02) : 103 - 110
  • [34] STEERENBERG PA, 1991, IN VIVO, V5, P655
  • [35] FUNCTIONAL DIVERSITY OF LYMPHOCYTE-T DUE TO SECRETION OF DIFFERENT CYTOKINE PATTERNS
    STREET, NE
    MOSMANN, TR
    [J]. FASEB JOURNAL, 1991, 5 (02) : 171 - 177
  • [36] TALMADGE JE, 1987, CANCER RES, V47, P5725
  • [37] RESPONSE OF RESTING HUMAN PERIPHERAL-BLOOD NATURAL-KILLER CELLS TO INTERLEUKIN-2
    TRINCHIERI, G
    MATSUMOTOKOBAYASHI, M
    CLARK, SC
    SEEHRA, J
    LONDON, L
    PERUSSIA, B
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1984, 160 (04) : 1147 - 1169
  • [38] PERITUMOR INTERLEUKIN-2 CAUSES SYSTEMIC THERAPEUTIC EFFECT VIA INTERFERON-GAMMA INDUCTION
    VAAGE, J
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1991, 49 (04) : 598 - 600
  • [39] IMMUNOLOGICAL ASPECTS OF FIBROSIS IN MOUSE MAMMARY CARCINOMAS
    VAAGE, J
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (01) : 69 - 74
  • [40] VAAGE J, 1988, CANCER RES, V48, P2193